药品製造市场规模、份额、成长分析、按配方类型、按给药途径、按处方类型、按药物开发、按分销管道、按地区 - 行业预测，2025-2032 年

2023年药品製造市场规模将为5,720.9亿美元，从2024年的6,630.5亿美元成长到2032年的2,1,588.2亿美元，复合年增长率预计将成长15.9%。

由于关键的医疗需求以及研究、开发和药品生产的增加，全球药品製造市场仍然强劲。关键的成长要素包括人口成长、慢性病盛行率上升以及医疗技术的重大进步。对创新药物、个人化治疗和生技药品的追求正在进一步增强市场活力。此外，扩大医疗基础设施、旨在改善医疗保健机会的政府倡议以及增加对製造设施的投资正在推动市场成长。然而，该行业面临严格的法律规范、定价压力和智慧财产权问题等可能阻碍整体进展的挑战。这种复杂的情况为製药业相关人员带来了机会和挑战。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 抑制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 监管环境
• 专利分析
• 案例研究
• 客户和购买标准分析
• 贸易分析

药品製造市场规模：依配方种类及复合年增长率（2025-2032）

• 市场概况
• 口服製剂
  • 锭剂
  • 胶囊
  • 粉末
• 注射
  • 液体注射
  • 冷冻干燥注射液
• 局部製剂
  • 奶油
  • 软膏
  • 凝胶
• 吸入製剂
  • 干粉吸入器 (DPI)
  • 定量喷雾吸入器(MDI)
• 其他的
  • 栓剂
  • 修补

药品製造市场规模：依管理途径及复合年增长率（2025-2032）

• 市场概况
• 口服
• 胃肠外的
• 局部的
• 吸入
• 经皮的
• 其他的

药品製造市场规模：依处方种类及复合年增长率（2025-2032）

• 市场概况
• 处方药
• 非处方药 (OTC)

药品製造市场规模：依药品开发及复合年增长率（2025-2032）

• 市场概况
• 临床前开发
• 临床试验
  • 第一阶段
  • 第二阶段
  • 第三阶段
• 核准
• 商业化生产

药品製造市场规模：依分销通路及复合年增长率（2025-2032）

• 市场概况
• 医院药房
• 零售药房
• 网路药房
• 其他的

药品製造市场规模：按地区及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2022-2024）

主要企业简介

• Pfizer Inc.（USA）
• Novartis AG（Switzerland）
• Roche Holding AG（Switzerland）
• Sanofi SA（France）
• Merck & Co., Inc.（USA）
• GlaxoSmithKline plc（UK）
• Johnson & Johnson（USA）
• AstraZeneca plc（UK）
• Eli Lilly and Company（USA）
• AbbVie Inc.（USA）
• Bristol-Myers Squibb Company（USA）
• Bayer AG（Germany）
• Amgen Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim GmbH（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novo Nordisk A/S（Denmark）
• Astellas Pharma Inc.（Japan）
• CSL Limited（Australia）

结论和建议

Pharmaceutical Manufacturing Market size was valued at USD 572.09 Billion in 2023 and is poised to grow from USD 663.05 Billion in 2024 to USD 2158.82 Billion by 2032, growing at a CAGR of 15.9% during the forecast period (2025-2032).

The global pharmaceutical manufacturing market remains robust, driven by essential healthcare demands and a surge in research, development, and drug production. Key growth factors include an increasing population, a rising incidence of chronic diseases, and significant advancements in medical technology. The pursuit of innovative drugs, personalized treatments, and biologics is further enhancing market dynamics. Additionally, the expansion of healthcare infrastructure, government initiatives aimed at improving healthcare access, and rising investments in manufacturing facilities are fueling market growth. Nevertheless, the sector faces challenges such as stringent regulatory frameworks, pricing pressures, and intellectual property rights issues that could hinder overall progress. This complex landscape presents both opportunities and hurdles for stakeholders in the pharmaceutical industry.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmaceutical Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmaceutical Manufacturing Market Segmental Analysis

Global Pharmaceutical Manufacturing Market is segmented by formulation type, route of administration, prescription type, drug development, distribution channel and region. Based on formulation type, the market is segmented into oral formulations, injectable formulations, topical formulations, inhalation formulations and others. Based on route of administration, the market is segmented into oral, parenteral, topical, inhalation, transdermal and others. Based on prescription type, the market is segmented into prescription drugs and over-the-counter (OTC) drugs. Based on drug development, the market is segmented into preclinical development, clinical trials, regulatory approval and commercial manufacturing. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmaceutical Manufacturing Market

A key driver of the global pharmaceutical manufacturing market is the escalating demand for healthcare products and medications across the globe. The expanding global population, combined with a rise in chronic diseases and infectious conditions, has sparked a significant increase in the need for pharmaceuticals. Furthermore, advancements in medical technology and a growing aging demographic further elevate the demand for new and innovative treatments. In response to this escalating market need, pharmaceutical manufacturers are compelled to enhance their production capacities, invest in research and development, and implement cutting-edge manufacturing technologies, ultimately fostering robust market growth.

Restraints in the Pharmaceutical Manufacturing Market

A significant challenge facing the pharmaceutical manufacturing market is the stringent regulatory framework enforced by governments and regulatory agencies. These bodies mandate rigorous standards to ensure the safety, efficacy, and quality of pharmaceutical products, demanding substantial investments in infrastructure, quality assurance processes, and meticulous documentation. Failure to comply with these regulations can lead to severe penalties and tarnish a company's reputation. Additionally, the intricate and lengthy approval process for new drugs can slow down product launches, ultimately delaying access to vital medications for patients. These regulatory hurdles create barriers for new entrants and elevate the overall costs and timelines associated with pharmaceutical manufacturing.

Market Trends of the Pharmaceutical Manufacturing Market

The global pharmaceutical manufacturing market is experiencing a significant trend towards personalized medicine and targeted therapies, fueled by technological advancements in genomics and a demand for individualized treatments. This shift has prompted manufacturers to adapt by embracing smaller batch production and flexible manufacturing processes. Concurrently, the focus on biologics and biosimilars is intensifying due to the growing prevalence of chronic diseases and the pursuit of innovative therapeutic solutions. Sustainability also plays a crucial role, as pharmaceutical companies increasingly prioritize eco-friendly practices, waste reduction, and energy efficiency to comply with stringent environmental regulations and align with evolving consumer expectations.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Patent Analysis
• Case Studies
• Customer & Buying Criteria Analysis
• Trade Analysis

Global Pharmaceutical Manufacturing Market Size by Formulation Type & CAGR (2025-2032)

• Market Overview
• Oral Formulations
  • Tablets
  • Capsules
  • Powders
• Injectable Formulations
  • Liquid Injections
  • Lyophilized Injections
• Topical Formulations
  • Creams
  • Ointments
  • Gels
• Inhalation Formulations
  • Dry Powder Inhalers (DPIs)
  • Metered Dose Inhalers (MDIs)
• Others
  • Suppositories
  • Patches

Global Pharmaceutical Manufacturing Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Parenteral
• Topical
• Inhalation
• Transdermal
• Others

Global Pharmaceutical Manufacturing Market Size by Prescription Type & CAGR (2025-2032)

• Market Overview
• Prescription Drugs
• Over-The-Counter (OTC) Drugs

Global Pharmaceutical Manufacturing Market Size by Drug Development & CAGR (2025-2032)

• Market Overview
• Preclinical Development
• Clinical Trials
  • Phase I
  • Phase II
  • Phase III
• Regulatory Approval
• Commercial Manufacturing

Global Pharmaceutical Manufacturing Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Global Pharmaceutical Manufacturing Market Size & CAGR (2025-2032)

• North America (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • US
  • Canada
• Europe (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Formulation Type, Route of Administration, Prescription Type, Drug Development, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations